Weakened growth rates of leading PPI inhibitors; domestic ones making advances
Although the growth rates of leading proton pump inhibitors(PPI) have been weakened, their domestic drugs seem to make an advance.
According to the UBIST data of the third quarter of 2015 on the 11th, 9 of the top 15 products had decreases in outpatient prescription.
AstraZeneca’s Nexium record...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
